The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Strategies and challenges for the next generation of therapeutic antibodies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“, and the associated properties of the Fc can also be modulated by engineering at several levels: altering the glycosylation status to regulate anti- and pro-inflammatory propertie”
BackgroundDrug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Genetic prognostic and predictive markers in colorectal cancer
Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., & Kerr, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2645 · Cited by 705
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550
FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications
Smith, K. G. C., & Clatworthy, M. R. (2010) · Nature Reviews Immunology · doi:10.1038/nri2762 · Cited by 543
Spector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
The IGF-I receptor in cell growth, transformation and apoptosis
Baserga, R., Hongo, A., Rubini, M., Prisco, M., & Valentinis, B. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00007-3 · Cited by 439
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 370
Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355
Engineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A. Y. W., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1553 · Cited by 298
Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass
Dillon, T. M., Ricci, M. S., Vezina, C., Flynn, G. C., Liu, Y. D., Rehder, D. S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709988200 · Cited by 291
Catumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274
Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A. T., Jack, A., Junutula, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205500 · Cited by 273
Vlasak, J., Bussat, M. C., Wang, S., Wagner-Rousset, E., Schaefer, M., Klinguer-Hamour, C., Kirchmeier, M., Corvaïa, N., Ionescu, R., & Beck, A. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.05.043 · Cited by 252
Self-citationPolson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Beck, A., Wagner-Rousset, E., Bussat, M.-C., Lokteff, M., Klinguer-Hamour, C., Haeuw, J.-F., Goetsch, L., Wurch, T., Dorsselaer, A., & Corvaia, N. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786411 · Cited by 246
Self-citationPedersen, M. W., Jacobsen, H. J., Koefoed, K., Hey, A., Pyke, C., Haurum, J. S., & Kragh, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1417 · Cited by 219
Hughes, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2813 · Cited by 191
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187
Optimization of Fc-mediated effector functions of monoclonal antibodies
Strohl, W. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.011 · Cited by 168
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies
Crawford, Y., & Ferrara, N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.004 · Cited by 156
The effect of Fc glycan forms on human IgG2 antibody clearance in humans
Chen, X., Liu, D., & Flynn, G. C. (2008) · Glycobiology · doi:10.1093/glycob/cwn120 · Cited by 123
Hughes, B. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3101 · Cited by 117
Discovery and development of biopharmaceuticals: current issues
Strohl, W. R., & Knight, D. M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.012 · Cited by 111
Evolution of anti- CD20 monoclonal antibody therapeutics in oncology
Oflazoglu, E., & Audoly, L. (2010) · mAbs · doi:10.4161/mabs.2.1.10789 · Cited by 109
Chartrain, M. M., & Chu, L. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786367 · Cited by 108
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 106
Wu, C., Hua, Y., Bose, S., Miller, R., Medina, L., Santora, L. C., & Ghayur, T. (2009) · mAbs · doi:10.4161/mabs.1.4.8755 · Cited by 94
How to systematically evaluate immunogenicity of therapeutic proteins – regulatory considerations
Jahn, E., & Schneider, C. K. (2009) · New Biotechnology · doi:10.1016/j.nbt.2009.03.012 · Cited by 93
When binding is enough: nonactivating antibody formats
Labrijn, A. F., Aalberse, R. C., & Schuurman, J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.010 · Cited by 90
Wagner‐Rousset, E., Bednarczyk, A., Bussat, M., Colas, O., Corvaïa, N., Schaeffer‐Reiss, C., DORSSELAER, A. V., & Beck, A. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.03.032 · Cited by 89
Self-citationGlycoFi's technology to control the glycosylation of recombinant therapeutic proteins
Beck, A., Cochet, O., & Wurch, T. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903413504 · Cited by 89
Self-citationStructural characterization of a human Fc fragment engineered for extended serum half-life
Oganesyan, V., Damschroder, M. M., Woods, R. M., Cook, K. E., Wu, H., & Dall’Acqua, W. F. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.026 · Cited by 89
Atmanène, C., Wagner‐Rousset, E., Malissard, M., Chol, B., Robert, A., Corvaı̈a, N., DORSSELAER, A. V., Beck, A., & Cianférani, S. (2009) · Analytical Chemistry · doi:10.1021/ac9007557 · Cited by 82
Self-citationMore is less—combining targeted therapies in metastatic colorectal cancer
Punt, C. J. A., & Tol, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.168 · Cited by 82
Considerations for the development of therapeutic monoclonal antibodies
Swann, P. G., Tolnay, M., Muthukkumar, S., Shapiro, M. A., Rellahan, B. L., & Clouse, K. A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.013 · Cited by 78
What's fueling the biotech engine—2008
Aggarwal, S. (2009) · Nature Biotechnology · doi:10.1038/nbt1109-987 · Cited by 62
European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK
Reichert, J. M., Beck, A., & Iyer, H. V. (2009) · mAbs · doi:10.4161/mabs.1.5.9630 · Cited by 61
Self-citationEconomic issues with follow-on protein products
Lanthier, M. L., Behrman, R. E., & Nardinelli, C. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2636 · Cited by 46
Zhang, B., Harder, A. G., Connelly, H. M., Maheu, L. L., & Cockrill, S. L. (2009) · Analytical Chemistry · doi:10.1021/ac902466z · Cited by 45
Zuraw, B. L., Yasothan, U., & Kirkpatrick, P. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3125 · Cited by 45
Beck, A., Wurch, T., & Corvaı̈a, N. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786420 · Cited by 38
Self-citationWurch, T., Lowe, P. R., Caussanel, V., et al. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786385 · Cited by 31
Self-citationmAb therapeutic products and risk management
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10628 · Cited by 28
Manufacture of recombinant polyclonal antibodies
Rasmussen, S. K., Rasmussen, L. K., Weilguny, D., & Tolstrup, A. B. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9331-8 · Cited by 26
Antibody-based identification of cell surface antigens: targets for cancer therapy
Loo, D. T., & Mather, J. P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.011 · Cited by 24
Antibody-drug conjugates ace the tolerability test
Damle, N. K. (2008) · Nature Biotechnology · doi:10.1038/nbt0808-884 · Cited by 18
Insulin-like growth factor receptor type I as a target for cancer therapy
Corvaïa, N. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s382 · Cited by 13
5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland
Beck, A., Reichert, J. M., & Wurch, T. (2010) · mAbs · doi:10.4161/mabs.2.2.11302 · Cited by 12
Self-citationInsulin-Like Growth Factor Receptor Type I as a Target for Cancer Therapy
Goetsch, L., & Corvaïa, N. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.265 · Cited by 8
4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland
Beck, A., Hanala, S., & Reichert, J. M. (2009) · mAbs · doi:10.4161/mabs.1.2.7890 · Cited by 7
Self-citation
Cited by
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Self-citationScott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Characterization of Therapeutic Antibodies and Related Products
Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A., & Sanglier-Cianférani, S. (2013) · Analytical Chemistry · doi:10.1021/ac3032355 · Cited by 587
Self-citationRohloff, J. C., Gelinas, A. D., Jarvis, T. C., Ochsner, U. A., Schneider, D. J., Gold, L., & Janjic, N. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.49 · Cited by 533
Aptamer-based targeted therapy
Zhu, G., & Chen, X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.005 · Cited by 522
Metadata
- Authors
- Beck, A., Wurch, T., Bailly, C., & Corvaia, N.
- Venue
- Nature Reviews Immunology
- Published
- 2010-05
- Volume
- 10
- Issue
- 5
- Pages
- 345-352
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2091229935
- Cited by
- 847
- References
- 68
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.